NasdaqCM - Nasdaq Real Time Price USD

Alpha Cognition Inc. Common Stock (ACOG)

5.04

+0.12

+(2.44%)

As of 10:30:06 AM EDT. Market Open.

Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

VANCOUVER & DALLAS, April 10, 2025--Alpha Cognition Inc. (Nasdaq: ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strat

Business Wire 14 days ago

ACOG
+2.44%
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024

Dallas, Texas--(Newsfile Corp. - April 1, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition had a strong 2024 after raising $52.8M and uplisting to NASDAQ, significantly enhancing its capital base and market visibility. It completed commercial manufacturing for its lead product ZUNVEYL (benzgalantamine), secured a new U.S. patent extending exclusivity through ...

Newsfile 22 days ago

ACOG
+2.44%
Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

VANCOUVER, British Columbia, March 31, 2025--Alpha Cognition Inc. (Nasdaq: ACOG) ("Alpha Cognition", or the "Company") today announced its financial results for the fourth quarter and full year ended December 31, 2024.

Business Wire 24 days ago

ACOG
+2.44%
Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

VANCOUVER, British Columbia & DALLAS, March 19, 2025--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2024 on March 31, 2025 after close of market.

Business Wire last month

ACOG
+2.44%
Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease

VANCOUVER, British Columbia & DALLAS, March 18, 2025--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced the official commercial launch of ZUNVEYL, a new treatment for mild to moderate Alzheimer’s disease. This milestone marks a major step forward in the company’s mission to provide innovative and accessible solutions for patients and caregivers — and to deliver new hope to the millions impacted by Al

Business Wire last month

ACOG
+2.44%
Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory

We came across a bullish thesis on Alpha Cognition Inc. Common Stock (ACOG) on Twitter by BullishDoctor. In this article, we will summarize the bulls’ thesis on ACOG. Alpha Cognition Inc. Common Stock (ACOG)’s share was trading at $5.75 as of March 4th. ACOG’s forward P/E was 16.05 according to Yahoo Finance. ZUNVEYL, a prodrug of Galantamine, […]

Insider Monkey last month

ACOG
+2.44%
Alpha Cognition Inc. (NASDAQ:ACOG) surges 13%; retail investors who own 46% shares profited along with institutions

Key Insights Significant control over Alpha Cognition by retail investors implies that the general public has more...

Simply Wall St. 2 months ago

ACOG
+2.44%
Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease

VANCOUVER, February 12, 2025--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition" (ACI), or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent titled "Coated Tablets for pH-Dependent Release of Benzgalantamine."

Business Wire 2 months ago

ACOG
+2.44%
Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)

Dallas, Texas--(Newsfile Corp. - January 30, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners initiates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition Inc. reported significant progress in 2024 so far, marked by key financial and corporate milestones. Alpha Cognition received approval for its flagship Alzheimer's therapy ZUNVEYL (benzgalantamine), successfully raised $4.5M in financing, and completed the necessary preparations for ...

Newsfile 2 months ago

ACOG
+2.44%
OTC Markets Group Announces Quarterly Index Performance and Rebalancing

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated financial markets for 12,000 U.S. and global securities, today announced the fourth quarter 2024 performance and quarterly rebalancing of the OTCQX® and OTCQB® indexes, including the OTCQX Canada Index and the OTCQX Dividend Index. The OTCQX Composite Index (.OTCQX), a benchmark for the overall OTCQX Best Market, was down 9.8% in Q4 2024. 32 new companies joined the Index while 31 companies we

GlobeNewswire 2 months ago

ADUR

TZUP

TSSI
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

VANCOUVER, British Columbia & DALLAS, January 14, 2025--Alpha Cognition Inc. (Nasdaq: ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; Rommel Fernandez, Vice President of Corporate Strategy and Operations; and Kurt Grady, Vice President of Medical Affairs. These hires

Business Wire 3 months ago

ACOG
+2.44%
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China

VANCOUVER, British Columbia & DALLAS, January 08, 2025--Alpha Cognition, Inc. (Nasdaq: ACOG) ("ACI" or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, and China Medical System Holdings Limited (CMS) (867.HK), a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability in the People’s Republic of China, today announced an exclusive licensing agreement for the

Business Wire 3 months ago

ACOG
+2.44%
Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call

DALLAS, January 06, 2025--Alpha Cognition Inc. (Nasdaq: ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced it will host an investor update call on Tuesday, January 28th, 2025 at 4pm EST to present its commercial launch strategy for ZUNVEYL (benzgalantamine), an FDA-approved treatment for mild-to-moderate Alzheimer’s disease (AD). The call will focus on the company’s plans t

Business Wire 3 months ago

ACOG
+2.44%
Alpha Cognition Announces Partial Exercise of Over-allotment Option

VANCOUVER, British Columbia & DALLAS, December 16, 2024--Alpha Cognition Inc. (Nasdaq: ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced that the underwriters of its underwritten U.S. public offering (the "Offering") have partially exercised their over-allotment option to purchase an additional 488,506 common shares at the public offering price of US$5.75 per share for an

Business Wire 4 months ago

ACOG
+2.44%
Alpha Cognition Announces Voluntary Delisting from CSE

VANCOUVER, British Columbia & DALLAS, December 12, 2024--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition", or the "Company"), announces that in connection with the Company’s listing on the Nasdaq Capital Market the Company will voluntarily delist its common shares from the Canadian Securities Exchange.

Business Wire 4 months ago

ACOG
+2.44%
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

VANCOUVER, British Columbia & DALLAS, December 11, 2024--Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG) ("Alpha Cognition" [ACI], or the "Company"), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced interim preclinical data that supports the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI). The interim data provides evidence of benefit for ALPHA-1062, in the treatment of mTBI resulting

Business Wire 4 months ago

ACOG
+2.44%

Performance Overview

Return	ACOG	S&P 500 (^GSPC)
YTD	-14.43%	-7.45%
1-Year	-28.00%	+7.33%
3-Year	-28.00%	+27.43%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Alpha Cognition Inc. Common Stock (ACOG)

Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024

Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease

Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory

Alpha Cognition Inc. (NASDAQ:ACOG) surges 13%; retail investors who own 46% shares profited along with institutions

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease

Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)

OTC Markets Group Announces Quarterly Index Performance and Rebalancing

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call

Alpha Cognition Announces Partial Exercise of Over-allotment Option

Alpha Cognition Announces Voluntary Delisting from CSE

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

Performance Overview